Why this matters to buyers
Buyers of generic pharmaceuticals have a defined two-year window of duty-free treatment for qualifying goods, after which a significant tariff increase to 200% is planned. This provides a clear timeline for supply chain planning and cost assessment.
Recommended buyer actions
- Conduct a detailed cost-benefit analysis of sourcing strategies over the announced two-year duty-free period versus the post-tariff period.
- Explore opportunities to qualify goods for duty-free treatment under the current rules.
- Develop contingency plans for sourcing and pricing models assuming the 200% tariff implementation.
Original source context
The president said Tuesday he would maintain duty-free treatment for qualifying goods the next two years before hiking the tariffs in ensuing years.
Read the original report · Supply Chain Dive